Ravichandran Kadayam Ramakrishnan, MD
Radiation Oncology · Mcallen
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 9 years
- Ohio State University College of Medicine, 2017
Offices
1 location · Texas Oncology PA · 1,001 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ramakrishnan’s office at (956) 687-5150 to ask if they take your plan before you enroll.
California Medical Board record
Licence A159857 · Current
Licensed to practise in California · since 2018 · expires 2026-12-31 · Ohio State University College of Medicine.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$490,901 in 2022
Medicaid paid $490,901 for 4,926 billed services this clinician did in 2022, up to 335 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,859 | $475,170 |
| Short return visit (20+ min) | 1,577 | $8,958 |
| Return visit (30+ min) | 447 | $3,360 |
| Short return visit | 827 | $2,424 |
| New patient visit (30+ min) | 135 | $980 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 81 | $9 |
| 2022 | 4,926 | 6 | 335 | $490,901 |
| 2021 | 4,854 | 23 | 402 | $492,014 |
See the largest Medicaid services in earlier years
2021
| Clinic visit/encounter, all-inclusive | 1,831 | $458,214 |
| Short return visit (20+ min) | 1,307 | $16,701 |
| Return visit (30+ min) | 394 | $6,498 |
| Short return visit | 441 | $3,530 |
| New patient visit (30+ min) | 118 | $3,193 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 47 | $869 |
| Long return visit (40+ min) | 25 | $642 |
| Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use | 114 | $513 |
| Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use | 21 | $499 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 18 | $363 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 19 | $265 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 39 | $234 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 188 Part D prescriptions in 2021.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2023 | 29 | 21 | None | None | $3,421 |
| 2022 | 635 | 111 | None | None | $59,059 |
| 2021 | 188 | 64 | 0% (0) | 10% | $15,660 |
| 2018 | 22 | 11 | None | None | $341 |
| 2017 | 11 | None | None | None | $9,143 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 15 drugs
| Atorvastatin | 56 | $692 | $12 |
| Amlodipine Besylate | 35 | $477 | $14 |
| Diclofenac | 17 | $403 | $24 |
| Gabapentin | 26 | $359 | $14 |
| Levothyroxine | 20 | $354 | $18 |
| Losartan | 25 | $351 | $14 |
| Metformin | 55 | $330 | $6 |
| Tamsulosin | 20 | $318 | $16 |
| Famotidine | 14 | $233 | $17 |
| Omeprazole | 11 | $227 | $21 |
| Metoprolol | 15 | $164 | $11 |
| Lisinopril | 15 | $103 | $7 |
| Alendronate | 13 | $84 | $6 |
| Hydrochlorothiazide | 13 | $60 | $5 |
| Furosemide | 13 | $53 | $4 |
2021: 1 drug
| Metformin | 32 | $110 | $3 |
Money from drug and device companies
$532 in 2025
| 2025 | 14 | 17 | None | $532 |
| 2024 | 3 | 3 | None | $299 |
| 2021 | 1 | 1 | None | $19 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Spaceoar Vue System - 10ml | $120 | 1 payment
|
| Integra LifeSciences | Codman Certas | $64 | 1 payment
|
| Janssen Biotech | Tecvayli | $52 | 2 payments
|
| Daiichi Sankyo | Enhertu | $50 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $45 | 2 payments
|
| Genmab U.S. | Epkinly | $29 | 1 payment
|
See all 17 published payments
| Daiichi Sankyo | Meals · 2025-10-21 | Enhertu | $22 |
| Integra LifeSciences | Meals · 2025-10-16 | Codman Certas | $64 |
| Array Biopharma | Meals · 2025-10-06 | Xalkori | $23 |
| Daiichi Sankyo | Meals · 2025-08-29 | Enhertu | $28 |
| Janssen Biotech | Meals · 2025-08-22 | Talvey | $22 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-07 | Stivarga | $21 |
| Merck Sharp & Dohme | Meals · 2025-07-24 | Keytruda | $21 |
| Pfizer | Meals · 2025-07-23 | Ibrance | $21 |
| Karyopharm Therapeutics | Meals · 2025-07-23 | Xpovio | $24 |
| Merck Sharp & Dohme | Meals · 2025-07-10 | Keytruda | $25 |
| Lilly USA | Meals · 2025-07-09 | Verzenio | $22 |
| Taiho Oncology | Meals · 2025-07-03 | Lonsurf | $17 |
| Syndax Pharmaceuticals | Meals · 2025-07-02 | None | $23 |
| Janssen Biotech | Meals · 2025-06-27 | Tecvayli | $29 |
| Genmab U.S. | Meals · 2025-06-25 | Epkinly | $29 |
| Genentech USA | Meals · 2025-06-03 | Itovebi | $21 |
| Boston Scientific | Meals · 2025-01-24 | Spaceoar Vue System - 10ml | $120 |
See earlier years (2024, 2021)
2024: $299
| Elekta | None | $216 | 1 payment
|
| Boston Scientific | Spaceoar System | $53 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $30 | 1 payment
|
2021: $19
| Novo Nordisk | Ozempic | $19 | 1 payment
|
Professional record
- NPI
- 1508390816
- Licence
- CA 159857California A159857: Current · expires 2026-12-31
- Trained
- Ohio State University College of Medicine, 2017 · 9 years ago
- Group
- Texas Oncology PA
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2085R0001X (2085R0001X); General practice (208D00000X); Student in a training program (390200000X)
- Mailing address
- 88 Golden Ash Way, Gaithersburg, MD, 20878
- NPI first listed
- 2017-04-13
- NPI last updated
- 2025-05-15
- NPI record certified
- 2025-05-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 88 Golden Ash Way, Gaithersburg, MD, 20878